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Abstract
Aims To estimate the incidence of early treatment diabetic retinopathy study (ETDRS) level 47 and 53 and progression to
treatment with panretinal photocoagulation (PRP) for proliferative DR (PDR).
Methods Log-linear regression was used to estimate the incidence of level 47–53 or worse for 33,009 people with diabetes
(PWD) in Gloucestershire during 2013–2016 by calendar year and diabetes type, based on the first recording. Progression
was analysed in Gloucestershire and Bristol with a parametric survival analysis examining the association of baseline and
time-varying demographic and clinical factors on time to PRP after the first recording of level 47–53.
Results Incidence decreased from 0.57 (95% confidence intervals (CI) 0.48–0.67) per 100 PWD in 2013 to 0.35 (95% CI
0.29–0.43) in 2016 (p < 0.001). For progression, 338 eligible PWD from Gloucestershire and 418 from Bristol were followed for
a median of 1.4 years; 78 and 83% had Type 2 diabetes and a median (interquartile range) of 15 (10–22) and 17 (11–25) years
duration of diagnosed diabetes respectively. Three years from the incident ETDRS 47–53, 18.9% and 17.2% had received PRP
respectively. For Gloucestershire, severe IRMA and updated mean HbA1c were associated with an increase in the risk of
initiating PRP (hazard ratio 3.14 (95% CI: 1.60–6.15) and 1.21 (95% CI: 1.06–1.38 per 10mmol/mol) respectively).
Conclusion This study provides additional understanding of this population and shows that a high proportion of patients
with ETDRS levels 47–53 need to be monitored as they are at high risk of progressing to PDR.
Introduction
In the UK, 6% of the population have a diagnosis of dia-
betes [1]. Diabetic retinopathy (DR) is a microvascular
complication that is a major cause of blindness and vision
loss in the working-age group [2]. In the UK, all people
with a diagnosis of diabetes registered with a primary care
physician are offered annual digital photographic screening
by the NHS diabetic eye screening programme (DESP) in
their area from the age of 12 years. The local programmes
need to meet standards [3] set by the NHS DESP of mini-
mum attendance of 75% per year and 92% over 3 years. The
South West of England has a population of 5.3 million
people, 600,000 in Gloucestershire and 900,000 in Bristol
and the surrounding area. Each area is served by one DESP
and one hospital eye service (HES) with 33,000 people with
diabetes (PWD) and 44,000 PWD, respectively. This study
used retrospective data from the two HESs and the Glou-
cestershire DESP. The Bristol and Weston DESP changed
their software supplier in October 2013 making it impos-
sible to analyse DESP data from the Bristol area.
Moderately severe non-proliferative DR (NPDR) and
severe NPDR are classified as early treatment diabetic reti-
nopathy study [4] (ETDRS) level 47 and 53, respectively.
They are classified by the presence and severity of venous
beading, intraretinal microvascular abnormalities (IRMA),
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and multiple haemorrhages compared to standard photos—the
ETDRS produced standard photos to compare lesions e.g.,
standard photograph 8A for IRMA and 2A for haemorrhages.
The treatment recommended by the UK Royal College of
Ophthalmologists [5] for proliferative DR (PDR) is panretinal
photocoagulation (PRP) with a few patients treated at level 53
where there is concern about patient compliance [6]. Mod-
erately severe NPDR is not amenable to eye-specific treat-
ment though patients are advised that the risk of progression
to sight-threatening retinopathy will be reduced if glycaemic
control is optimal. This study aims to characterise the mod-
erately severe and severe NPDR population since this infor-
mation is currently limited.
Materials and methods
Gloucestershire DESP (GDESP) has offered annual digital
photographic screening to all eligible people in Glouces-
tershire since 1998. Screening is carried out in healthcare
settings including primary care practices and clinics in
hospitals. Gloucestershire hospital eye service (HES) clinics
are run in the two main hospitals and five other clinics
across Gloucestershire. Bristol HES clinics are run in
Bristol Eye Hospital and five other clinics across the region.
Patient and public involvement—Gloucestershire has a
group of three PWD who we have consulted within the
design and writing up phase of this study.
Study design and study population
A retrospective, observational analysis using data from PWD
aged 18 years and older in Gloucestershire and Bristol was
conducted between 1 January 2013 and 31 December 2016.
The cohort was defined as those in 2012 or later who have not
yet reached EDTRS level 47 in their worst eye. The Glou-
cestershire cohort consisted of patients who had GDESP
electronic screening medical records (ESMR—OptoMize
from Northgate Ltd., Hemel Hempstead, UK) and HES
electronic medical records (EMR—Medisoft Limited, Leeds,
UK). The Bristol HES cohort had HES EMR (Medisoft) data.
Data collection pseudonymised data were extracted from
the Gloucestershire ESMR and EMR and from the Bristol




Incidence of moderately severe NPDR or worse (ETDRS
level ≥47) in 2013–2016.
Patient population analysed: Patients from the Glouces-
tershire cohort.
The patients at risk had one complete DR prior assess-
ment with DR of ETDRS level <47 in both eyes. Incident
cases (numerator) were defined as first-time ETDRS level
≥47 in at least one eye was recorded during 2013–2016. This
included those of level 53 and above who had progressed
from <47 directly to a higher level. Patients who already
received PRP, anti-VEGF, or steroids were excluded.
Incidence estimates were calculated with 95% confidence
intervals (CI) over time using log-linear (Poisson) regres-
sion models and also analysed by diabetes type.
Secondary analyses
Time to initiate PRP treatment among patients with ETDRS
47 or 53 in the Gloucestershire and Bristol cohorts.
Patient population analysed: patients from both centres
were included if they had a first recording of moderately
severe—severe NPDR diagnosis (ETDRS level 47–53) in
2013–2016 and at least one subsequent follow-up record.
Those with a previous record of ETDRS level ≥47 were
excluded, as were those who had been treated with PRP,
intravitreal injection treatment of VEGF inhibitors or steroids.
Hazard ratios (with 95% CI) were calculated from uni-
variate and multivariate Weibull models (fitted using for-
ward stepwise selection) to evaluate time to initiation of
PRP treatment from the first record of DR of ETDRS level
47–53 in the worse eye. Patients were censored at death,
moving out of the area, loss to follow-up (those still
registered but were last seen over a year before study
endpoint), or end of 2016, whichever came first.
The updated HbA1c for an individual at any time point is
the weighted mean of all previous HbA1c measures for that
patient since the earliest HbA1c assessment (baseline)
during the study period, with more weight given to more
recent assessments. All secondary analyses were run sepa-
rately for Gloucestershire and Bristol because of extra data
available from the Gloucestershire site e.g., HbA1c, ethni-
city, and ESMR data.
Statistical analyses were performed using Stata 16. Eth-
ics approval was granted by the NHS Health Research
Authority for this study with IRAS project ID: 236309.
Results
Primary analysis
In Gloucestershire 33,009 PWD met the inclusion/exclusion
criteria for the incidence analysis in 2013–2016. They were
aged 67 (56–76) years (median, interquartile range), 57%
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male, 94% had Type 2 diabetes, with 6 (2–10) years duration
of diagnosed diabetes.
For each calendar year, the incidence of ETDRS level
≥47 was estimated (Table 1). Incidence decreased from 0.57
(95% CI: 0.48–0.67) per 100 PWD in 2013 to 0.35 (95%
CI: 0.29–0.43) in 2016, with incidence rate ratio (IRR) for
calendar year 0.86 (95% CI: 0.79–0.93) p < 0.001. When
split by diabetes type, the downward trend with time was
only found amongst those with T2DM (p= 0.587 for trend
with time for T1DM). For Gloucester people with T2DM,
incidence of ETDRS level ≥47 decreased from 0.47 (95%
CI: 0.39–0.57) per 100 PWD in 2013 to 0.26 (95% CI:
0.20–0.33) in 2016 (IRR for calendar year 0.83 (95% CI:
0.76–0.91) p < 0.001).
Secondary analysis
In the Gloucestershire cohort, 477 were newly diagnosed
with level 47 or worse: at the time of first recording, 110
(23.1%) were level 47, 228 (47.8%) level 53 and 139
(29.1%) PDR (level > 61). Among the Bristol cohort, 550
people were newly diagnosed with level ≥47: 227 (41.3%)
were level 47, 191 (34.7%) level 53 and 132 (24.0%) PDR
(level > 61). Those with PDR at first recording were
excluded from the progression analysis. Thus, 756 people
(338 from Gloucestershire and 418 from Bristol) met the
inclusion criteria for the secondary analysis, with a median
follow up time of 1.4 years for both Bristol and Glouces-
tershire. Baseline characteristics are shown in Table 2.
Of the 756 participants, 46 (13.6%) from Gloucestershire
and 39 (9.3%) from Bristol were subsequently treated for
DR with PRP. Of the 671 participants who did not go on to
receive PRP treatment for DR:
(a) Gloucestershire cohort—at their last assessment, 6
(2.1%) had untreated PDR, 251 (86.0%) level 47–53, 32
(11.0%) mild NPDR and 3 (1.0%) no DR. The latter three
were felt to be unlikely and so were audited by PHS. One
was considered an error, the second a vein occlusion (not
DR) and the third caused by lesions outside the photo-
graphic fields of the second assessment. During follow-up,
24 (7.1%) died, 45 (13.3%) were not seen again in over a
year, and 5 (1.5%) moved away.
(b) Bristol cohort—at their last assessment, 7 (1.9%) had
untreated PDR, 315 (83.3%) level 47–53, 62 (16.4%) mild
NPDR and 1 (0.3%) no DR. The one with no DR was
audited by the Bristol Clinical Lead and was considered an
error in the original diagnosis. During follow-up, 8 (2.1%)
died (although the recording of this was incomplete) and 61
(16.1%) were not seen again in over a year or moved away
(specific data unavailable).
Kaplan–Meier plots of time to treatment for patients with
incident ETDRS level 47–53 (baseline) are shown in Fig. 1.
In Gloucestershire, after 1 year 6.4% (95% CI: 4.1–9.9%)
and after 3 years 18.9% (95% CI: 14.2–25.0%) had received
PRP. In Bristol, after 1 year 5.7% (95% CI: 3.7–.6%) and
after 3 years 17.2% (95% CI: 11.9–24.4%) had received
PRP. There was no difference in these rates between
Gloucestershire and Bristol (p= 0.43).
Table 1 Incidence of moderately-severe NPDR or worse (ETDRS level ≥47), per 100 Gloucestershire people with diabetes.
Number of
Gloucestershire PWD
at risk* of developing
incident moderately
severe NPDR or
worse in at least one
eye during the
respective year




Overall± 23,860 25,683 27,175 29,393
T1DM 1432 1578 1685 1761
T2DM 22,410 24,030 25,394 27,501
New ETDRS level 47
or worse in at least
one eye
Overall n 136 119 119 103 0.86
Incidence 0.57 0.46 0.44 0.35 (0.79–0.93)
(95% CI) (0.48–0.67) (0.39–0.55) (0.37–0.52) (0.29–0.43) p < 0.001
T1DM n 31 26 30 32 0.96
Incidence 2.2 1.7 1.8 1.8 (0.81–1.12)
(95% CI) (1.5–3.1) (1.1–2.4) (1.2–2.6) (1.3–2.6) p= 0.587
T2DM n 105 93 89 71 0.83
Incidence 0.47 0.39 0.35 0.26 (0.76–0.91)
(95% CI) (0.39–0.57) (0.32–0.47) (0.28–0.43) (0.20–0.33) p < 0.001
PWD people with diabetes, NPDR non-proliferative diabetic retinopathy, T1DM Type 1 diabetes mellitus, T2DM Type 2 diabetes mellitus, CI
confidence interval;
*Those at risk were those on the GDESP register during the respective year, with at least one assessment that year and where all prior assessments
showed DR of ETDRS level <47 in both eyes.
±Includes those with ‘other’ and ‘unknown’ diabetes types.
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The results from the univariate and multivariate analyses
of time to PRP are shown in Tables 3 and 4, the latter
finding the following risk factors for requiring PRP: (a) in
Gloucestershire those with IRMA > 8a and those with
continuously higher HbA1c levels. (b) In Bristol those who
were younger, those with VB in either eye, those with DR
of ETDRS level 53 in the better eye (at baseline), and those
with maculopathy in either eye.
Discussion
This study aimed to characterise moderately severe and
severe NPDR patients since this information is currently
limited. Wong et al. [7] reported that detailed reporting of
ETDRS levels was only present in 4% of studies reviewed.
Although International Coding Systems [8, 9] do contain
DR levels, the EMR system used in the two HESs is unique
in that it requires the clinician to fill in a structured
assessment form based on lesion identification and the
system assigns an ETDRS level.
We were unable to find any studies in the literature that
specifically reported on the incidence of levels ≥47 although
a number of studies have reported on the incidence of PDR
in those who had not had PDR at baseline.
In Gloucestershire, the incidence of ETDRS level ≥47
decreased during the study period. Although there were low
numbers of non-attenders they are more likely to have
higher levels of retinopathy [10, 11]. It was not possible to
estimate incidence rates in the Bristol cohort because of the
lack of primary care screening data to determine the
denominator.
In 1989, Klein reported the 4-year incidence of PDR
[12, 13] was 11% in those diagnosed <30 years of age, and
7% for insulin users and 2% for non-insulin users ≥30 years
of age. In 2008, Klein reported the 25-year incidence of
PDR [14] in Type 1 diabetes was 42%.
In 2010, Varma [15] reported the 4 years incidence of
PDR from the Los Angeles Latino Eye Study of Type 2
diabetes was 5.3%. In 2014 Broe reported [16] the 16 years
incidence of PDR in Type 1 diabetes was 31%.
The 4-year incidence of ETDRS level ≥47 was 1.45%
(95% CI: 1.32 to 1.58). 94% had Type 2 diabetes with a
median age of 67 (IQR 56–76) years. This is lower than the
2% who developed PDR for non-insulin users ≥30 years in
the 1989 Klein paper and lower than the 5.3% reported by
Varma. The most likely reason for this and the reduction
over the period of the study is better glycaemic and blood
pressure control.
In the ETDRS study [4], 3 years progression to PDR was
47.6% for level 47 and 71.1% for level 53.
Klein reported [17] the 10 years progression to PDR in
those diagnosed <30 years was 82.0% for level 47 and
Table 2 Baseline patient characteristics of those in the secondary
(survival) analysis; Gloucestershire (N= 338) and Bristol (N= 418)






N % N %
Gender Female 142 42.0 175 41.9
Male 196 58.0 243 58.1






Diabetes type Recorded 338 100 390 93.3
T1DM 74 21.9 65 16.7
T2DM 264 78.1 325 83.3
HbA1c (mmol/mol) Recorded 327 96.7 n/a
b
Median (IQR) 68 (56–85)
Mean (SD) 71.6 (20.4)
Time since diagnosis
of diabetes (years)
Recorded 338 (100%c) 219 (52.4%)
Median (IQR) 15 (10–22) 17 (11–25)
Mean (SD) 16.2 (9.4) 19.1 (12.2)
Age (years) Median (IQR) 63 (52–72) 63 (52–73)
Mean (SD) 61.4 (14.8) 61.7 (14.6)
VA (Log MAR)d Recorded 338 (100%) 417 (99.8%)
Median (IQR) 0.1 (0.0–0.2) 0.1 (0.0–0.2)
Mean (SD) 0.13 (0.20) 0.11 (0.17)
Retinopathy grade in
the better eye
No DR (ETDRS 10) 0 0.0 4 1.0
Mild NPDR
(ETDRS 20–35)
75 22.2 115 27.5
Moderate NPDR
(ETDRS 43)
142 42.0 117 28.0
Moderately severe NPDR
(ETDRS 47)
48 14.2 105 25.1
Severe NPDR (ETDRS 53) 73 21.6 77 18.4




M0 in both eyes 165 48.8 125 29.9
M1 in at least one eye 173 51.2 293 70.1
Presence of venous
beading in either eye
No VB 203 60.1 277 54.3
VB in at least one eye 135 39.9 191 45.7
Presence of IRMA in
either eye
No IRMA 30 8.9 134 32.1
IRMA < 8a in at least
one eye
112 33.1 179 42.8
IRMA > 8a in at least
one eye




No multiple haemorrhages 251 74.3 187 44.7
Multiples haemorrhages in
at least one eye
87 25.7 231 55.3
Baseline was the time when a participant was first found to have DR of
ETDRS level 47–53 in at least one eye.
T1DM Type 1 diabetes mellitus, T2DM Type 2 diabetes mellitus,
NPDR non-proliferative diabetic retinopathy, VB venous beading,
IRMA intraretinal microvascular abnormalities, IQ inter-quartile range,
VA visual acuity.
aFor Bristol, 18.9% had missing ethnicity. Of those with ethnicity
recorded, 98.2% were recorded as Caucasian. The research team felt
that this was not representative of the true ethnicity distribution in
Bristol and so removed ethnicity from Bristol analyses.
bHbA1c data was not available for participants from Bristol.
c3 Gloucestershire participants had no diabetes diagnosis date
available, for those date of DESP registration was used as a proxy.
dNot all participants had a VA measure on their EMR of precision 2
decimal places. One Gloucestershire participant had a VA of count
fingers, this was converted to 2.0 Log MAR.
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75.0% for level 53, and for those diagnosed ≥30 years was
80.5% for level 47 and 61.5% for level 53. The UKPDS
study [18] reported 6 years progression to PDR requiring
PRP was 60 and 90% from levels 47 and 53 in one eye
respectively. An EMR study from 19 UK hospitals reported
[19] the 3 years progression to proliferative was 16.1% for
eyes with level 43 (n= 6986), 31.6% for eyes with level 47
(n= 1764) and 55.8% for eyes with level 53 (589).
Fig. 1 Time to PRP laser from
Incident ETDRS level 47–53.
Gloucestershire (A) and
Bristol (B).
Table 3 Risk factors for
initiating PRP treatment:
univariate analyses.






Sex: female 1.56 (0.87–2.78) 0.138 1.32 (0.71–2.48) 0.385
Duration of diabetes (per 5 years)a 1.00 (0.85–1.16) 0.950 0.87 (0.71–1.06) 0.163
Age (per 5 years) 0.86 (0.78–0.95) 0.003 0.79 (0.71–0.87) <0.001
Type of diabetes: T1DMb 1.27 (0.66–2.44) 0.483 2.14 (1.04–4.42) 0.040
Retinopathy level in the better eye (ref: ETDRS 10–35)c
ETDRS 43 1.23 (0.56–2.71) 0.601 2.13 (0.81–5.61) 0.125
ETDRS 47 1.11 (0.37–3.31) 0.856 1.72 (0.60–4.95) 0.316
ETDRS 53 1.75 (0.74–4.16) 0.205 3.96 (1.49–10.57) 0.006
Ethnicity: Caucasian 0.83 (0.30–2.31) 0.716 n/a
Time-varying factors
VB in at least one eye vs. none 1.54 (0.86–2.76) 0.145 2.85 (1.50–5.42) 0.001
IRMA status (ref: no IRMA in both eyes)
IRMA < 8a in at least one eye 1.51 (0.33–6.92) 0.592 1.58 (0.68–3.65) 0.287
IRMA > 8a in at least one eye 4.90 (1.17–20.52) 0.029 4.21 (1.85–9.57) 0.001
MH in at least one eye vs. none 1.62 (0.86–3.05) 0.132 1.86 (0.99–3.52) 0.055
VA (per 0.1 increment in
LogMAR score)
1.05 (0.94–1.17) 0.411 0.94 (0.74–1.19) 0.612
Maculopathy: M1 in either eye 1.14 (0.60–2.16) 0.695 2.04 (1.09–3.83) 0.026
Updated mean HbA1c (per 10 mmol/
mol)d
1.24 (1.09–1.42) 0.001 n/a
DR diabetic retinopathy, HR hazard ratio, T1DM Type 1 diabetes mellitus, VB venous beading, IRMA
intraretinal microvascular abnormalities, MH multiple haemorrhages, VA visual acuity, PRP panretinal
photocoagulation.
aFor Bristol, the diabetes diagnosis date was only available for 219 (52.4%) participants, of which 23
received PRP.
bFor Bristol, diabetes type was known for 390 (93.3%) participants, of which 31 received PRP.
cFour patients in Bristol had no DR in their fellow eye; the significant HR for having ETDRS 53 in the fellow
eye remained significant when removing those with no DR from the reference group.
dFor Gloucestershire, the updated mean HbA1c was available was 327 (96.7%) participants, of which 45
received PRP.
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In this study 18.9% of patients in Gloucestershire and
17.2% in Bristol had received PRP within 3 years of
developing DR of ETDRS level 47–53 in their worst-
affected eye, indicating slower progression in this group
than previously reported.
UK Screening studies [20–23] tend to report the inci-
dence of referable retinopathy which is standardised across
UK screening programmes as level ≥43 and maculopathy.
Hence these studies have limited data on levels 47–53. A
screening study [24] in two diabetes clinics in Northern
Italy refers at level ≥47 and maculopathy and they reported
a 21.1% 10 years referral rate if level 43 was present at first
examination.
It is well known that high levels of HbA1c [12–14, 16, 18]
are a major risk factor for progression of DR. Klein [14],
Wong [7] and Kiore [25] all reported lower rates of DR
progression in later time periods which is felt to be due to
better control of glycaemia and blood pressure.
We found prominent IRMA (>8A) and HbA1c as the
two highest risk factors for progression in the Glouces-
tershire cohort and that rates of progression are much
lower than earlier time periods. This is in agreement with
previous literature [4, 26], but this study helps to quantify
incidence and progression in the modern era where gly-
caemic and blood pressure treatment guidelines are tigh-
ter. The Bristol multivariate analysis indicated a negative
relationship with age and progression; this goes against
common knowledge of the disease. Two possible reasons
for this result are: (a) the true relationship with age may
not fit the model assumptions and so more sophisticated
modelling may be needed, or (b) instead of indicating that
younger people are more likely to progress, it may be
indicating that older people do not survive long enough
for the disease to progress this far. The Bristol multi-
variate analysis was limited by the unavailability of
HbA1c data. Hence the Gloucestershire results have been
taken as primary to form conclusions and Bristol is sup-
portive, warranting further research. In conclusion, the
real-world data in this study is unique in the level of detail
of ETDRS levels that are recorded and analysed. It can
answer patients’, ophthalmologists’ and DESP managers’
queries related to current clinics that monitor those with
moderately severe—severe NPDR (EDTDRS levels
47–53). By looking at data from 2012 to 2016 this study
gives recent data demonstrating that a high proportion of
patients with ETDRS levels 47–53 progress to PDR
requiring further medical interventions (currently PRP).
These patients have a currently unmet medical need to
slow down progression or to reverse their condition,
especially for those with the highest risk of progression
with poorly controlled diabetes. However further research
is needed to help clinicians identify ways in which the risk
of progression can be reduced.
Summary
What was known before
● This study aimed to characterise moderately severe and
severe NPDR patients.
● This information is currently limited.
● Detailed reporting of ETDRS levels is only present in
4% of studies.
What this study adds
● The real-world data in this study is unique in the level
of detail of ETDRS levels that are recorded and
analysed.




Risk factor Multivariate HR (95% CI) p-value
IRMA > 8a in either eye vs. IRMA < 8a or none (time-varying) 3.14 (1.60–6.15) 0.001
Updated mean HbA1c (per 10 mmol/mol, time-varying) 1.21 (1.06–1.38) 0.005
Bristol
Age (per 5 years, time-varying) 0.79 (0.70–0.88) <0.001
VB in either eye vs. none (time-varying) 2.71 (1.43–5.16) 0.002
ETDRS 53 in fellow eye vs. ETDRS ≤ 47 (at baseline) 2.33 (1.17–4.62) 0.016
M1 in either eye vs. M0 in both (time-varying) 2.02 (1.07–3.81) 0.029
Results are from multivariate Weibull models (through forwarding step-wise selection) for time to PRP
treatment for DR after having DR of ETDRS level 47–53 recorded in Gloucestershire and Bristol people.
DR diabetic retinopathy, HR hazard ratio, T1DM Type 1 diabetes mellitus, VB venous beading, IRMA
intraretinal microvascular abnormalities, MH multiple haemorrhages, VA visual acuity, PRP panretinal
photocoagulation.
aBased on 327 participants as a result of having updated mean HbA1c in the model.
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● The association of baseline and time-varying demo-
graphic and clinical factors on time to PRP after the first
recording of level 47–53.
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